Last reviewed · How we verify
Bromocriptine-QR
Bromocriptine-QR is a quick-release formulation of bromocriptine, a dopamine D2 receptor agonist that reduces prolactin secretion and modulates circadian rhythm regulation.
Bromocriptine-QR is a quick-release formulation of bromocriptine, a dopamine D2 receptor agonist that reduces prolactin secretion and modulates circadian rhythm regulation. Used for Hyperprolactinemia, Prolactin-secreting pituitary adenoma (prolactinoma), Cardiovascular risk reduction in type 2 diabetes (phase 3 indication).
At a glance
| Generic name | Bromocriptine-QR |
|---|---|
| Also known as | quick-release (QR) bromocriptine (cycloset) |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Dopamine D2 receptor agonist |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Bromocriptine acts as a dopamine agonist at D2 receptors in the tuberoinfundibular pathway, suppressing prolactin release from the anterior pituitary. The quick-release (QR) formulation is designed to provide rapid onset of action. Beyond prolactin suppression, bromocriptine has been investigated for effects on circadian rhythm and metabolic regulation, particularly in the context of cardiovascular and metabolic disease.
Approved indications
- Hyperprolactinemia
- Prolactin-secreting pituitary adenoma (prolactinoma)
- Cardiovascular risk reduction in type 2 diabetes (phase 3 indication)
Common side effects
- Nausea
- Dizziness
- Headache
- Orthostatic hypotension
- Fatigue
Key clinical trials
- Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM (PHASE3)
- Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects (PHASE4)
- Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes (PHASE2)
- QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes (PHASE4)
- Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy (PHASE4)
- Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |